NDAORALCAPSULE, PELLETS
Approved
Sep 2023
Lifecycle
Growth
Competitive Pressure
8/100
Clinical Trials
20
Mechanism of Action
Cytochrome P450 3A Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Clinical Trials (5)
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Started Dec 2023
190 enrolled
Carcinoma, Non-Small-Cell Lung
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Started Oct 2023
420 enrolled
Metastatic Uveal Melanoma
Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC
Started Dec 2021
275 enrolled
Non-Small Cell Lung CancerALK-positiveSAF-189s
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
Started Sep 2021
220 enrolled
Carcinoma, Non-Small-Cell Lung
Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS)
Started Apr 2021
25 enrolled
Healthy Participants
Loss of Exclusivity
LOE Date
Nov 6, 2029
44 months away
Patent Expiry
Nov 6, 2029